- Report
- March 2024
- 184 Pages
Global
From €3257EUR$3,374USD£2,794GBP
€3619EUR$3,749USD£3,104GBP
- Report
- January 2024
- 200 Pages
Global
From €4826EUR$5,000USD£4,140GBP
- Report
- November 2023
- 145 Pages
Global
From €2412EUR$2,499USD£2,069GBP
- Clinical Trials
- April 2024
- 170 Pages
Global
From €1930EUR$2,000USD£1,656GBP
- Report
- June 2023
- 338 Pages
Global
From €7239EUR$7,500USD£6,210GBP
- Report
- October 2023
- 145 Pages
Global
From €3040EUR$3,150USD£2,608GBP
- Report
- December 2023
- 140 Pages
Global
From €4295EUR$4,450USD£3,684GBP
- Report
- August 2020
- 114 Pages
Global
From €4102EUR$4,250USD£3,519GBP
- Report
- April 2023
- 180 Pages
Global
From €3137EUR$3,250USD£2,691GBP
- Report
- May 2021
- 250 Pages
Global
From €8639EUR$8,950USD£7,410GBP
- Report
- August 2022
- 115 Pages
Global
From €4343EUR$4,500USD£3,726GBP
- Report
- July 2018
- 30 Pages
China
From €2123EUR$2,200USD£1,821GBP
- Report
- December 2018
- 48 Pages
Global
From €3373EUR$3,495USD£2,894GBP
- Report
- May 2023
- 110 Pages
Global
From €3500EUR$3,884USD£3,107GBP
- Report
- April 2024
- 50 Pages
Global
From €2558EUR$2,650USD£2,194GBP
Latanoprost is a medication used to treat glaucoma and ocular hypertension, two common optical disorders. It is a prostaglandin analog, meaning it works by increasing the outflow of fluid from the eye, reducing intraocular pressure. It is available as an eye drop, and is usually administered once daily. Common side effects include eye irritation, redness, and darkening of the eyelashes.
Latanoprost is a widely used medication for the treatment of glaucoma and ocular hypertension. It is generally well tolerated and has been shown to be effective in reducing intraocular pressure. It is available in generic form, as well as under various brand names.
In the Latanoprost market, there are several companies that produce and market the medication. These include Allergan, Pfizer, Sun Pharmaceuticals, and Merck. Show Less Read more